NCI-MATCH, or the Molecular Analysis for Therapy Choice, is a landmark clinical trial aimed at advancing personalized cancer treatment. This trial, spearheaded by the National Cancer Institute (NCI), focuses on assigning cancer treatments based on the genetic abnormalities of a patient's tumor rather than the cancer type. NCI-MATCH represents a paradigm shift from traditional cancer treatment methodologies that typically rely on the cancer's location in the body.
